SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.
The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement - 24 June 2016
Palo Alto, California, USA and Salisbury, UK, June 24, 2016— Carbylan Therapeutics, Inc. (Nasdaq: CBYL) and KalVista Pharmaceuticals Ltd., a privately-held biopharmaceutical company, announced today that they, together with the shareholders of KalVista, have entered into a definitive share purchase agreement pursuant to which the shareholders of KalVista will become the majority owners of Carbylan. If approved, Carbylan will be renamed KalVista Pharmaceuticals, Inc.
Dementia Discovery Fund invests in Gen2 Neuroscience Ltd - 3 June 2016
The Dementia Discovery Fund, managed by SV Life Sciences, is an innovative global investment fund launched in October 2015 to develop disease modifying drugs for dementia, announces an investment in new drug discovery company Gen2 Neuroscience Ltd.